Responses
Poster Presentation
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas
Compose a Response to This Article
Other responses
No responses have been published for this article.